Key points are not available for this paper at this time.
Carbohydrate antigen 19-9 (CA 19-9) is the sole FDA-approved serum biomarker for early detection, progression, and treatment response of pancreatic ductal adenocarcinoma (PDAC, pancreatic cancer). It is more specific than other serum biomarkers for PDAC. Understanding the clinical relevance of genetic variants and other conditions on CA 19-9 expression is thus critical for proper interpretation. This review covers PDAC risk assessment, screening, early diagnosis and treatment monitoring with a focus on CA 19-9 and genetic factors that influence serum levels with or without PDAC.
Whitcomb et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: